Draft:Effector tumor antigen-specific T cells
 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 2,768 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Submission declined on 27 March 2025 by Sophisticatedevening (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Tumor antigen-specific T cells (TASTs) are the mainstay of the body's specific recognition of cancer cells and can be used as biomarkers for efficacy prediction of immunotherapy/chemoimmunotherapy combinations. [1]Although these T cells can specifically recognize tumor antigens, not all TASTs have cytotoxic functions. Specific recognition of tumor antigens is structural specificity, whereas the ability to kill tumor cells containing such antigens after recognition is functional specificity.[2]
Based on structural and functional specificity, TASTs were categorized into three groups: (1) Effector Tumor Antigen-Specific T Cells (ETASTs) are both specifically recognize tumor antigens and specifically kill tumor cells containing the corresponding antigen after recognition of the tumor antigen.
(2) Regulatory tumor antigen-specific T cells (RTASTs) can only specifically recognize tumor antigens, but instead of killing cancer cells after recognition, they inhibit the function of ETASTs.[3]
(3) Anergy tumor antigen-specific T cells (ATASTs) can only specifically recognize tumor antigens, but do not have the function of killing tumor cells after recognition.[4]
Recent studies have shown a positive correlation between the levels of ETASTs in vivo or in peripheral blood and the efficacy and prognosis of combined immunotherapy/chemoimmunotherapy in cancer patients after combined immunotherapy/chemoimmunotherapy. ETASTs are the mainstay of the body's specific recognition and specific killing of cancer cells, and are the real players in immunotherapy. Successful immunotherapy relies on reactivating or increasing the levels of ETASTs. Detection of ETASTs in the peripheral blood of cancer patients may be an ideal biomarker to predict the efficacy and prognosis of combined immunotherapy/chemoimmunotherapy.[5]
References
[edit]- ^ Ahmadzadeh, Mojgan; Johnson, Laura A.; Heemskerk, Bianca; Wunderlich, John R.; Dudley, Mark E.; White, Donald E.; Rosenberg, Steven A. (2009-08-20). "Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired". Blood. 114 (8): 1537–1544. doi:10.1182/blood-2008-12-195792. ISSN 0006-4971. PMC 2927090. PMID 19423728.
- ^ Zeng, Weibiao; Wang, Jin; Chen, Zhike; Yang, Jian; Zhu, Ao; Zheng, Yan; Chen, Xianlan; Liu, Yuhan; Wu, Leilei; Xie, Yufeng; Ju, Sheng; Chen, Jun; Ding, Cheng; Li, Chang; Tong, Xin (January 2025). "Efficient Predictor for Immunotherapy Efficacy: Detecting Pan-Clones Effector Tumor Antigen-Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens". Advanced Science. 12 (2): e2409913. doi:10.1002/advs.202409913. ISSN 2198-3844. PMC 11727128. PMID 39498880.
- ^ "Antigen-Specific Cell Enrichment", SpringerReference, Berlin/Heidelberg: Springer-Verlag, 2011, doi:10.1007/springerreference_31813 (inactive 28 March 2025), retrieved 2025-03-28
{{citation}}: CS1 maint: DOI inactive as of March 2025 (link) - ^ Jenkins, M K; Chen, C A; Jung, G; Mueller, D L; Schwartz, R H (1990-01-01). "Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody". The Journal of Immunology. 144 (1): 16–22. doi:10.4049/jimmunol.144.1.16. ISSN 0022-1767. PMID 2153162.
- ^ Wang, Jin; Zeng, Weibiao; Xue, Jiao; Zhu, Ao; Chen, Xianlan; Zheng, Yan; Liu, Yuhan; Qin, Songbing; Zhao, Jun; Liu, Mi (2024-12-03). "Efficient Biomarker for Immunotherapy: Measuring Broad Clones Effector Tumor Antigen-Specific T Cells in the Blood of Esophageal Cancer Patients". Analytical Chemistry. 96 (48): 19056–19065. Bibcode:2024AnaCh..9619056W. doi:10.1021/acs.analchem.4c04049. ISSN 0003-2700. PMID 39561375.